The effects of AMPA receptor antagonists in models of stroke and neurodegeneration-Reference-Cited by-同舟云学术

The effects of AMPA receptor antagonists in models of stroke and neurodegeneration

Published:2005-09 Issue:1-2 Volume:519 Page:58-67
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Gressens Pierre,Spedding Michael,Gigler Gabor,Kertesz Szabolcs,Villa Pascal,Medja Fadia,Williamson Toni,Kapus Gabor,Levay Gyorgy,Szenasi Gabor,Barkoczy Jozsef,Harsing Laszlo G.

Publisher

Elsevier BV

Subject

Pharmacology

Reference49 articles.

1. Cardiotrophin-1 requires LIFRα to promote survival of mouse motoneurons purified by a novel technique;Arce;J. Neurosci. Res.,1999

2. Pretreatment but not posttreatment with GYKI 52466 reduces functional deficits and neuronal damage after global ischemia in rats;Block;J. Neurol. Sci.,1996

3. CNQX increases GABA-mediated synaptic transmission in the cerebellum by an AMPA/kainate receptor-independent mechanism;Brickley;Neuropharmacology,2001

4. Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia;Buchan;Neuroreport,1991

5. Blockade of the AMPA receptor prevents CA1 hippocampal injury following severe but transient forebrain ischemia in adult rats;Buchan;Neurosci. Lett.,1991

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy;Frontiers in Neurology;2023-07-06

2. Inhibition of non-NMDA ionotropic glutamate receptors delays the retinal degeneration in rd10 mouse;Neuropharmacology;2018-09

3. Persistent therapeutic effect of a novel α5-GABAA receptor antagonist in rodent preclinical models of vascular cognitive impairment;European Journal of Pharmacology;2018-09

4. Systematic review of the pharmacological agents that have been tested against spreading depolarizations;Journal of Cerebral Blood Flow & Metabolism;2018-04-20

5. Tetrahydroisoquinolines;Privileged Structures in Drug Discovery;2018-03-09